ArticleAnnals of translational medicine2022
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- CD13 identifies S100A4Biology direct · 2026Article
- ASPM promotes the progression of esophageal squamous cell carcinoma by upregulating the expression of HMMR.Cancer cell international · 2026Article
- Article
- Telomere-based Risk Model for Prognosis Prediction in Clear Cell Renal Cell Carcinoma.Current medicinal chemistry · 2026Article
- Analysis of the relationship between serum LAMC2, TROAP and clinical stages and prognosis of non-muscle invasive bladder cancer.Open medicine (Warsaw, Poland) · 2026Article
- TROAP aggravates chemoresistance of colorectal cancer cells via lipogenesis by PI3K/Akt pathway and histone acetylation.Functional & integrative genomics · 2025Article
- Integrated analysis reveals survival-related genes promoting cholangiocarcinoma progression via G2/M cell cycle, with validation of cyclin B1 in tumor proliferation.Scientific reports · 2025Article
- Promotion of hepatocellular carcinoma stemness and progression by abnormal spindle-like microcephaly-associated protein via the Wnt/β-catenin pathway.Journal of gastrointestinal oncology · 2024Article
- Evaluating trophinin associated protein as a biomarker of prognosis and therapy response in renal cell carcinoma.BMC cancer · 2024Article
- LncRNA ERICD interacts with TROAP to regulate TGF-β signaling in hepatocellular carcinoma.Heliyon · 2024Article
- TROAP Promotes the Proliferation, Migration, and Metastasis of Kidney Renal Clear Cell Carcinoma with the Help of STAT3.International journal of molecular sciences · 2023Article
- Insights from the protein interaction Universe of the multifunctional "Goldilocks" kinase DYRK1A.Frontiers in cell and developmental biology · 2023Review
- The neurological and non-neurological roles of the primary microcephaly-associated protein ASPM.Frontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although increasing evidence supports a vital role for assembly factor for spindle microtubules (ASPM) and trophinin-associated protein (TROAP) in the tumorigenesis of some cancers, no systematic pancancer analyses of ASPM and TROAP have been performed. Thus, we aimed to investigate the potential functions of ASPM and TROAP across 31 cancer types. Methods: Based on datasets from The Cancer Genome Atlas (TCGA), Human Protein Atlas (HPA), Gene-Cloud of Biotechnology Information (GCBI) and Gene Expression Omnibus (GEO), we employed an array of bioinformatics methods to explore the potential oncogenic roles of ASPM and TROAP. Results: ASPM and TROAP, which were highly expressed in most cancers and presented a strict positive correlation, led to a decreased life expectancy among cancer patients. ASPM and TROAP both regulated cell replication in the S&G2 phase of the cell cycle. Through a protein-protein interaction network (PPI) analysis of ASPM and TROAP, we found that cell division cycle 20 (CDC20) was regulated by TROAP and functioned upstream of ASPM. Thus, TROAP can regulate the role of ASPM in cancers. Conclusions: The ASPM and TROAP have a significant positive correlation and similar expression profiles, and promote tumor malignancy and development in the S&G2 phase of the cell cycle. Since ASPM is one of the downstream targets of TROAP, TROAP and especially ASPM may be potential tumor makers and promising targets for therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.